In February 2024, the professional team from VCRO assisted the client in submitting an allogeneic mesenchymal stem cell product for clinical trials in the field of frailty to TFDA. The team successfully obtained TFDA approval to proceed with Phase I/II clinical trials, helping the client smoothly transition to the clinical trial phase.
In February 2024, the professional team from VCRO assisted the client in submitting an allogeneic mesenchymal stem cell product for clinical trials in the field of frailty to TFDA. The team successfully obtained TFDA approval to proceed with Phase I/II clinical trials, helping the client smoothly transition to the clinical trial phase.
